Synbio International, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Synbio International, Inc. is a biotechnology company focused on synthetic biology solutions and related life sciences applications, with operations spanning multiple regions. Founded in 2001 and headquartered in Paris, Île-de-France, FR, the company develops and commercializes engineered biological products and services for healthcare, agriculture, and industrial applications, emphasizing biologically derived components, bioprocess technologies, and related support services. Main products and services: - Core biotech platforms: synthetic biology design/build, strain engineering, and optimization services; proprietary biological parts, devices, and systems for development and scale-up; post-production processing including purification and formulation of biological products. - Therapeutic and health-related solutions: engineered probiotic strains, postbiotic formulations, and biopharmaceutical development services; collaboration on biologics discovery, development, and manufacturing support; regulatory and quality assurance consulting tied to biologics programs. - Industrial and agricultural applications: bio-based chemicals, enzyme development, and fermentation workflows; plant and animal health products leveraging engineered microbes; environmental biotech solutions for waste processing and remediation. - Manufacturing and CDMO capabilities: contract development and manufacturing organization services for biotech products; process development, scale-up, analytical method development, and regulatory documentation support; supply chain and GMP-compliant production facilities. - Data, analytics, and advisory: genomic design data, simulation and modeling services, and technical due diligence for partner programs; regulatory pathway guidance and commercialization planning for biotech assets. Latest major company changes: - Strategic partnerships and collaborations: enters co-development agreements with biotech and pharmaceutical partners to advance engineered biologics and probiotic/ postbiotic products; expands alliance network to accelerate product commercialization. - Funding and corporate actions: completes or engages in funding rounds to support platform expansion and pipeline development; participates in acquisitions or restructurings to broaden capabilities in synthetic biology, fermentation, and downstream processing. - Product launches and service expansions: introduces new postbiotic and probiotic product lines under refined branding; launches enhanced CDMO services and scalable manufacturing processes for biotech assets. - Strategic shifts and geographic expansion: broadens international footprint, including expanded operations and collaborations in Europe and Asia; reinforces go-to-market strategy for global customers across healthcare, nutrition, and industrial biotech sectors. - Corporate reorganizations: undergoes organizational realignments to streamline R&D, manufacturing, and commercial functions; updates branding and product naming to reflect expanded capabilities. Additional context: - Industry and segments: biotechnology; synthetic biology; life sciences tools and solutions; probiotic and postbiotic research; bioprocess development and manufacturing; bio-based product commercialization. - Markets and customers: pharmaceutical and biotech developers, healthcare providers, food and beverage and nutraceutical manufacturers, agricultural and environmental biotech customers, and research institutions. - Geographic operations: headquarters in France with international activity across Europe and Asia; established collaborations and customer engagements in multiple regions, supported by global partners and distributors. - Subsidiaries and parent relationships: operates within a network of affiliates and partner organizations to deliver end-to-end biotech solutions; maintains strategic alliances that augment its platform capabilities.
Synbio International Secures DWAC and DRS Eligibility
Synbio Signs Agreement for a Proof-of-Concept Clinical Trial to Evaluate a Unique AI-Based Facial Analysis Screening Software for Mental Health Disorders
Synbio International Inc. Expands its Board of Directors and Strengthens its Clinical Leadership with the Appointment of Dr. Nick Vatakis
Synbio International Inc. Expands its Board of Directors and Strengthens its Clinical Leadership with the Appointment of Dr. Nick Vatakis
Synbio International Inc. Strengthens Strategic Alliance with FacialDx Inc. through Share Purchase and Warrant Agreements
NATURAL HARMONY FOODS INC. COMPLETES FINANCIAL AUDITS FOR 2022 & 2023
Natural Harmony Foods Inc. Completes Financial Audits for 2022 & 2023
Reduction of Outstanding Common Stock
NATURAL HARMONY FOODS INC. CHANGING NAME AND LOGO TO BETTER REFLECT ITS NEW STRATEGIC DIRECTION
Natural Harmony Foods Inc. Changing Name and Logo to Better Reflect Its New Strategic Direction
NATURAL HARMONY FOODS INC. SIGNS US$5,000,000 EQUITY FACILITY TO FUND GROWTH
NATURAL HARMONY FOODS INC. ANNOUNCES NEW STRATEGIC DIRECTION AND SETS THE STAGE FOR A REVOLUTION IN HEALTHCARE AND WELLNESS